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The  transfer  of a laboratory  process  into  a manufacturing  facility  is  one  of  the  most  critical  steps  required
for  the large  scale  production  of cell-based  therapy  products.  This  study  describes  the  ﬁrst  published
protocol  for scalable  automated  expansion  of  human  induced  pluripotent  stem  cell  lines  growing  in
aggregates  in  feeder-free  and  chemically  deﬁned  medium.  Cells  were  successfully  transferred  between
different  sites  representative  of research  and  manufacturing  settings;  and  passaged  manually  and  using
the  CompacT  SelecT  automation  platform.  Modiﬁed  protocols  were  developed  for  the  automated  systemeywords:
nduced pluripotent stem cells
eeder free
utomation
cale  up
and  the  management  of cells  aggregates  (clumps)  was  identiﬁed  as the  critical  step.  Cellular  morphology,
pluripotency  gene  expression  and  differentiation  into  the three  germ  layers  have  been used  compare  the
outcomes  of manual  and  automated  processes.
© 2014  The  Authors.  Published  by Elsevier  B.V.  Open access under CC BY license. anufacturing
. Introduction
Human induced pluripotent stem cells (hiPSC) are generated
rom reprogrammed ﬁbroblasts by overexpression of pluripotency
actors (Takahashi et al., 2007; Yu et al., 2007). These pluripo-
ent cells have the unique characteristic to self renew in vitro
hile maintaining the capacity to differentiate into a broad num-
er of cell types. By combining these unique properties, hiPSC
ould enable the generation of large quantity of cells for clinical
pplications. Furthermore, the possibility of generating hiPSC from
omatic cells using epigenetic reprogramming represents a unique
pportunity for personalized regenerative medicine. Indeed, these
luripotent stem cells could enable the production of patient
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Open access under CC BY license. speciﬁc cell types that are fully immuno-compatible with the orig-
inal donor thereby avoiding the need for immune suppressive
treatment after cell transplantation. Nevertheless, the practical,
ﬁnancial and temporal obstacles in producing and validating per-
sonalized clinical-grade hiPSC and their differentiated progeny
will almost certainly limit the feasibility of this approach. These
limitations could selectively restrict patient access to autologous
cell-based therapies (Faden et al., 2003). The creation of clinical
banks of hiPSC from donors that can provide HLA matching to
recipients is proposed as a strategy to attenuate the host immune
response to transplanted tissue (Lin et al., 2009; Taylor et al., 2005,
2011).
Similarly, hiPSC can be used to develop in vitro disease models,
allowing large scale studies otherwise restricted due to the limited
availability of primary cells and biopsy material. This application
has been proven useful to model neurodegenerative diseases, car-
diac syndromes and metabolic disorders in vitro for basic studies
and drug screening (Ebert et al., 2009; Moretti et al., 2010; Rashid
et al., 2010). However, each of these applications requires large
quantity of hiPSC produced in reproducible and standardized ways.
Indeed, expansion of hiPSC remains time and resources consuming
while experimental variability due to human intervention is almost
systematic.
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Process automation has been a key mechanism to achieve con-
rolled and standardized cell production. Successful automated
rotocols have been developed for the expansion of human mes-
nchymal stem cells (Thomas et al., 2007) and human embryonic
tem cells (hESC) (Thomas et al., 2009b). Scale up automation
nables scale out for conventional formats with predictable process
ariation and quality outcome by removing manual interventions.
owever, little work has been done in developing technologies
or automation and scale up of hiPSC for healthcare applications.
everal solutions and technologies have been developed for live
ell production in suspension platforms (Ratcliffe et al., 2012).
owever these are not readily adapted for cells growing in adher-
nt conditions. Furthermore, large scale production of hiPSC for
linical applications would require expansion in culture using clin-
cally compatible conditions in a reproducible way without loss
f function and in sufﬁcient numbers to create reproducible and
ost effective therapeutic products. Finally, passaging represent
he main difﬁculty to develop an automation platform to expand
iPSC since these cells must be propagated as aggregates/clumps
o maintain their integrity and quality (Beers et al., 2012). Indeed,
vidence indicates that hiPSC grown and harvested as single cells
re more likely to acquire genetic anomalies (Amps et al., 2011).
onsequently, standardization of cell counting and cell clump
ize measurement has proven to be impractical. Here, we have
ddressed all these issues by transferring an established man-
al method to grow hiPSC in feeder free and chemically deﬁned
edium onto an automated platform compatible with large scale
roduction. This study shows for the ﬁrst time that large scale auto-
ated production of hiPSC is possible without the need of single
ell dissociation thereby respecting their natural properties.
. Materials and methods
.1. Manual maintenance and passage of hiPSC in feeder free and
hemically deﬁned medium
hiPSC were cultured in feeder-free conditions using chemi-
ally deﬁned medium (CDM-PVA) with Activin A (10 ng ml−1, R&D
ystem) and FGF2 (12 ng ml−1, R&D Systems) – iPSC medium,
s previously described (Brons et al., 2007). The composition of
DM-PVA was 50% IMDM (Gibco) added to 50% F12 + GlutaMax-1
Gibco), supplemented with 1% lipid concentrate (Gibco), 7 g ml−1
f insulin (Roche), 15 g ml−1 of transferrin (Roche), 450 M of
onothioglycerol (Sigma) and 1 mg  ml−1 of Polyvinyl Alcohol
Sigma). Cells were harvested after 6 or 7 days of culture (dependent
n visually conﬁrmed conﬂuence) using 1 mg  ml−1 collagenase IV
Gibco) and 1 mg  ml−1 dispase (Gibco). Detached colonies were
spirated and pooled into a conical tube and washed with CDM-
VA medium. A second wash step was performed before colonies
ere gently broken down into smaller cell aggregates (clumps) by
ipetting and allowed to settle under gravity. It must be noted here
hat the aim was only to reduce the size of the aggregates and not
o reduce them to single cells. Cell clumps were plated at 1:10 split
atio to 0.1% porcine gelatin plates (Sigma), pre-coated with mouse
mbryonic ﬁbroblast medium containing 10% FBS (Biosera) for 24 h
t 37 ◦C and 5% (v/v) CO2. iPSC medium and 10 M of Y27632
Sigma) was added for the ﬁrst 48 h. Following this, maintenance
edium was replaced daily until readiness for the next passage.
his protocol is routinely used for 6 well plates and T-25 ﬂasks
Fig. 1)..2. Manufacturing platform and instrumentation
The CompacT SelecT (The Automation Partnership, UK) is a
ully automated cell culture platform which incorporates a smallchnology 173 (2014) 53–58
six-axis anthropomorphic robotic arm (Cell Therapy Manufacturing
Facility, 2011) that can access 90 T175 ﬂask and plate incubators,
controlled at 37 ◦C under an atmosphere of 5% (v/v) CO2 and humid-
ity. The system allows the automation of seeding, feeding and other
cell culture processes in order to maintain cell lines in standard
T175 cell culture ﬂasks. Flasks are bar-coded for identiﬁcation
and cell process tracking. Two  ﬂask decappers and ﬂask hold-
ers, automated medium pumping and an automatic cell counter
(Cedex®, Roche Innovatis AG, Germany) are integrated within a
high-efﬁciency particulate air (HEPA) ﬁltered cabinet to ensure
sterility. At Loughborough University, the CompacT SelecT has been
successfully used to culture many different cell types including
human mesenchymal cells and human embryonic stem cells (hESC)
(Thomas et al., 2007, 2009a,b). The CompacT SelecT has also been
shown to be successful at preventing contamination when the GMP
version of the CompacT SelecT passed the “sterile ﬁll” runs (Chandra
et al., 2012). The CompacT SelecT allows activities during cell cul-
ture such as seeding, media changes and measurement cells in a
controlled environment (Thomas, 2012). Thus this platform can
be used to expand and differentiate batches of cells to a tighter
speciﬁcation than manual cell culture (Liu et al., 2010).
2.3. Automated passage of hiPSC in feeder free and chemically
deﬁned medium using CompacT SelecT
The automation enables scale out for conventional formats with
predictable process variation and quality outcome by removing
manual interventions. The CompacT SelecT is a preferred platform
for development process friendly method of automating the cul-
ture of cells that grow in adherent conditions. The automation step
mimics the manual process and is therefore demonstrably simi-
lar to the manual cell culture steps. For many manual cell culture
protocols, there is a centrifugation step to concentrate the cell sus-
pension and allow for cells to be washed. However, in this instance,
cells grow in aggregates and do not require centrifugation as they
settle under gravity.
In order to transfer the culture protocol to the CompacT SelecT
it was  necessary to scale up from a T25 to a T175 ﬂask, media vol-
umes were scaled proportionally to ﬂask surface area, and work
within the restricted set of plasticware and the allowable posi-
tioning of the plasticware within the automated system (Fig. 1).
Operating conditions of the manual culture process were followed
as closely as possible (temperature, timing, splitting ratio, mixing,
volumes), however a number of detailed changes had to be made
to the manual protocol as are discussed later in the manuscript.
2.4. Differentiation of hiPSC into endoderm, mesoderm and
neuroectoderm
hiPSC were plated into gelatin plates pre coated with 10% FBS
and maintained for 24 h in iPSC medium before inducing differ-
entiation into the three germ layers: endoderm, mesoderm and
neuroectoderm as described previously (Vallier et al., 2009). Dif-
ferentiation was induced by supplementing CDM-PVA with Activin
(R&D System), bFGF (R&D System), BMP4 (R&D System), LY294002
(Promega), SB431542 (Tocris) and CHIR99021 (Stemgent) at differ-
ent times and concentrations (Supplementary Online Material).
Supplementary material related to this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.jbiotec.
2013.12.009.
2.5. ImmunochemistryhiPSC were ﬁxed for 20 min  at 4 ◦C in 4% paraformaldehyde
(PFA) and washed three times in PBS. Cells were incubated 1 h at
room temperature in PBS containing 10% donkey or goat serum
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Cig. 1. Protocol steps for manual passage of hiPSC using six well plates, T25 ﬂasks a
olumes of reagents and media were scaled up accordingly, the incubation time fo
ere  identiﬁed and are listed above.
depending on antibody, Serotec), for intra-cellular epitopes 0.1%
riton X-100 (Sigma) was added to the blocking solution. Cells
ere then subsequently incubated with primary antibodies diluted
n 1% serum in PBS overnight at 4 ◦C. Dilutions were as follows:
RA-1-60 (Santa Cruz, 1:100), OCT4 (Santa Cruz, 1:100), NANOG
R&D Systems, 1:100), and anti-SOX2 (R&D Systems, 1:100), SOX17
R&D Systems, 1:200), EOMES (Abcam, 1:100), BRAC (R&D Systems,
:100), MIXL1 (Abcam, 1:100), Nestin (Abcam, 1:100). Cells were
ashed 3 times in PBS and incubated with secondary antibodies,
lexa Fluor 568 (Invitrogen) and Alexa Fluor 488 (Invitrogen), for
 h at room temperature. Cells were washed three times with PBS
nd stained with Hoechst 33258 (Sigma, 1:10,000 diluted in PBS)
or 5 min. The cells were viewed in PBS using a Zeiss Axiovert 200M
icroscope.
.6. RNA extraction, reverse-transcriptase PCR and quantitative
CR
Total RNAs were extracted from hiPSC using the GenElute Mam-
alian Total RNA Miniprep Kit (Sigma). For each sample 0.5 g
f total RNA was reverse transcribed using Superscript II reverse
ranscriptase (Invitrogen). RNA and primer were denatured at 65 ◦C
or 5 min  and RT-PCR reaction mixtures incubated at 25 ◦C for
0 min, 42 ◦C for 50 min  and 70 ◦C for 10 min. qPCR was performed
sing Sensi Mix  Sybr Low Rox Kit (Bioline). A negative control that
ontained only water and a positive control that contained RNA
able 1
hanges made between protocols: T25 manual, T175 manual and T175 automated.
Incubation time (min) |
incubator temperature
(◦C)
Plasticware
used to wash
clumps
Time for col
settle down
after washin
T25 manual 30 | 37.5 Conical tube 5 
T175  manual 35 | 37.5 T175 ﬂask 10 
T175  automated 35 | 36.5 T175 ﬂask 10–15 5 ﬂasks. The original six well plate protocol was  scaled up for T25 and T175 ﬂasks.
5 ﬂasks increased and the 1 ml  tip replaced by 10 ml pipettes. The key parameters
extracted from human embryonic stem cells (H9-WiCell) were also
ran. The expression of the PBGD housekeeping gene was used to
normalize qPCR reactions.
3. Results and discussion
An human induced pluripotent stem cell line – BBHX8 (Vallier
et al., 2009), derived from adult human ﬁbroblasts using retroviral
reprogramming with OCT4, SOX2, KLF4 and c-MYC was  derived and
manually maintained at the Anne McLaren Laboratory for Regener-
ative Medicine (LRM), University of Cambridge. In order to develop
an automation process to expand hiPSC using CompacT SelecT, the
hiPSC line was transferred to the Centre for Biological Engineer-
ing (CBE), Loughborough University where it was further cultured
and passaged in T25 ﬂasks using the manual protocol established at
LRM (Brons et al., 2007). This line was subsequent scaled up to T175
ﬂasks (Fig. 1). When transferring to T175 ﬂasks, two  major limita-
tions of the CompacT SelecT were taken into consideration: (i) as
an alternative to the use of conical tubes the T175 ﬂask was used to
wash and pellet the cell clumps by gravity. This removed a process
step but required a protocol modiﬁcation that increased the time
required for settling of aggregates. (ii) 10 ml  pipettes were used
instead of 1000 l tips when breaking the cell clumps to a desir-
able size (Fig. 2). Cells were maintained using the manual protocol
in both T25 and T175 ﬂasks to show process transfer and scale up
within both facilities.
onies to
 by gravity
g (min)
Plasticware
used to break
clumps
Number of pipetting
movements to break
clumps
Split ratio
1000 l tips 5 1:10
10 ml pipette 5 1:10
10 ml pipette 7 1:7–1:5
56 F.A.C. Soares et al. / Journal of Biote
Fig. 2. Protocol steps for automated passage of hiPSC using ComppacT SelecT.
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Telected protocol for automated passage of hiPSC from mature colonies to broken
lumps passaged into new ﬂasks.
The manual process of expanding T175 ﬂasks was  executed
or three weeks to gain conﬁdence in the protocol before cells
ere transferred to the CompacT SelecT. A split ratio of 1:10 was
aintained and the cell clumps broken to the appropriate size by
he operator using a 10 ml  pipette (Table 1). However it become
vident that mimicking the breaking of cell clumps to the desir-
ble size by the operator would be the most difﬁcult step to
utomate.
To adapt the T175 manual protocol to the CompacT SelecT, four
terations of the automation protocol were written and tested in
he CompacT SelecT. The changes made in the four versions of the
utomated protocol were based on: (a) the time for the colonies to
ettle down by gravity after washing, (b) the distance of the pipette
rom the bottom of the ﬂask when removing diluted enzyme solu-
ion without aspirating the cells clumps, (c) the pipetting speed and
able 2
he four versions of the automated protocol showing the parameters changed in the prot
Time for colonies to
settle down by gravity
after washing (min)
Height from bottom
ﬂask to aspirate
enzymatic solution 
Version A 10 0.5 
Version B 15 5 
Version C 15 10 
Version D 15 10 chnology 173 (2014) 53–58
number of mixing steps required to achieve an homogeneous cell
suspension of the desirable cell clump size without the presence of
an undue number of single cells, and (d) the split ratio (Table 2).
To take into account the small volumes of some reagents and to
prevent inaccuracies of the dispensed volumes by a 10 ml pipette
or 1.6 mm bore tubing, the media formulation was mixed manu-
ally. Therefore, the automation platform was  used to dispense the
complete media.
In the ﬁrst version (A) of the automated protocol, several cell
clumps were lost during the washing steps as the time for cell
clumps to settle was  insufﬁcient, additionally several clumps were
aspirated due to the pipette reaching close to the bottom of the ﬂask
when aspirating the enzymatic solution. Care is essential during the
two washes in order to dilute the enzyme concentration without
aspirating cell clumps. Moreover the low speed of mixing was  insuf-
ﬁcient to break the clumps to the desired size. A higher split ratio
was used when comparing to manual protocol. This was  chosen
to account for any potential cell loss during the automation steps
described in the above paragraph (a)–(c). The following versions
(B–D) looked at improving Version A (Table 2) and subsequently
the outcome of the passage.
It proved difﬁcult to use the CEDEX cell counter to count clumps
of cells in order to passage cells based on cell count as the CEDEX
could not count the clumps accurately (data not shown). This
would have improved process reproducibility, however the meth-
ods available for counting cell aggregates/clump are not yet suitable
to be integrated within an automation platform.
A feature of the CompacT SelecT is its 90 T175 ﬂask carousel
incubators. While the robot placed the ﬂasks gently in the incuba-
tor carousel without disturbing the cells, as soon as the carousel
was rotated, cell clumps moved under centrifugal force to concen-
trate in parts of the ﬂask resulting in a heterogeneous distribution
of the cell clumps/colonies in the ﬂask; this in particular can result
in the growth of differentiated colonies. This observation showed
the importance of leaving the unattached cells in an undisturbed
condition and that even the slightest movement can result in a
heterogeneous distribution of the colonies.
Of the four ﬂasks/protocol versions (A–D) tested in the Com-
pacT SelecT, C was the best protocol based on colony morphology
and absence of differentiation 7 days after passage (Fig. 2). To fur-
ther assess the quality of the se cells when compared to manual
protocols (T25Manual and T175Manual), expression of pluripo-
tency markers was  analyzed using qPCR and immunochemistry.
These analyses showed high levels and homogenous expression of
pluripotency markers and morphology characteristic of hiPSC for
both manual and automated protocols (Fig. 3).
In addition, capacity of differentiation toward the three germ
layers was conﬁrmed by growing the hiPSC into culture con-
ditions inductive for endoderm, mesoderm and neuroectoderm
differentiation. Both manual protocols in T25 ﬂasks and the auto-
mated protocol in T175 ﬂasks showed homogeneous differentiation
of hiPSC into the three germ layers as observed by the change
of cell morphology and by the expression of endoderm mark-
ers: SOX17 and EOMES, mesoderm markers: BRACHURY and
MIXL1 and neuroectoderm markers: NESTIN and SOX2 (Fig. 4).
These results suggest that cells expanded with our automation
ocols.
 of
(mm)
Speed of mix  and ﬁnal dispense
of liquid in pipette to break
colonies in ﬁnal step (ml/s)
Split ratio
5 | 1 1:7
10 | 1 1:7
20 | 1 1:7
50 | 50 1:5
F.A.C. Soares et al. / Journal of Biotechnology 173 (2014) 53–58 57
Fig. 3. Characterization of hiPSC passaged using manual protocol in T25 ﬂasks and T175 ﬂasks and using automated passage in T175 ﬂasks. (A) Bright ﬁeld microscope images
of  hiPSC colonies passaged manually in T175 ﬂasks using the CompacT SelecT. Scale bar = 60 M.  (B) Expression of pluripotency genes by qPCR for the hiPSC passaged manually
in  T25 ﬂasks and T175 ﬂasks and passaged using automation in T175 ﬂasks. Three technical replicates were performed for each sample and all genes were normalized to PBGD
and  hESC. Scale bar = 20 M.  (C) Expression of pluripotency markers (SOX2, OCT4, TRA-160 and NANOG) analyzed by immunochemistry. Both analyses show no signiﬁcant
difference between the two manual and the automated protocol. Scale bar = 20 M. Abbreviation: hESC, human embryonic stem cells.
Fig. 4. Immunostaining analysis of the expression of endoderm, mesoderm and neuroectoderm markers in hiPSC passaged using manual protocol in T25 ﬂasks and using
a MES)
S viation
p
i
p
s
futomated passage in T175 ﬂasks. Expression of endoderm markers (SOX17 and EO
OX2)  in hiPSC for both manual and automated protocols. Scale bar = 20 M.  Abbre
rotocol retain the capacity to produce cell types with a clinical
nterest.
Considered together, these data suggest that the transfer of
rotocols between the two facilities was successful and that both
cale-up and automation protocols were shown to maintain cell
unction comparable to manually passaged hiPSC., mesoderm markers (BRAC and MIXL1) and neuroectoderm markers (NESTIN and
: T25M, T25 manual; T175AC, T175 automated.
4. Conclusion
In conclusion, we have successfully demonstrated a protocol
passaging hiPSC in an automated system, the CompacT SelecT,
with cells maintained as aggregates. This work has shown that
hiPSC can be passaged in an automated system without losing
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heir pluripotent capabilities. Cells maintained their characteris-
ic hiPSC morphology and expressed pluripotency markers both by
mmunochemistry and qPCR. Additionally, these cells maintained
he capacity to differentiate into the three germ layers (endoderm,
esoderm and neuroectoderm). The comparison between manual
nd automated conditions showed the maintenance and passaging
f hiPSC is feasible using the CompacT SelecT system, however
o improve reproducibility some detailed changes will have to be
mplemented. Further work is necessary to deﬁne more accurately
he critical protocol parameters and take account of the constraints
equired when generating fully functional hiPSC lines for clinical
pplications.
With respect to future automated solutions incubator design
ust take into account the current necessity of not disturbing cells
hat require to be grown as aggregates, such as hiPSC and that take
ime (potentially up to 24 h) to attach. Automation would most
ertainly beneﬁt from development of (conical) plastic vessels
f the volume necessary to accommodate cell suspensions from
175 ﬂasks as this could reduce the time for cell clumps to settle
nd thus speeding the passaging protocol. The option to use a
ipette with smaller bore than a 10 ml  pipette would assist the
ptimization of breaking cell clumps to the desirable size and
educe the single cell debris caused by pipetting. While these
odiﬁcations would be required to optimize the present protocol
o ensure maximum yields of cells, this study represents a proof of
rinciple that hiPSC can be expanded in clumps using automation
ithout loss of quality.
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